Skip to Content
Merck
  • Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.

Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.

American journal of obstetrics and gynecology (2012-09-11)
Steve N Caritis, Hyagriv N Simhan, Yuan Zhao, Dwight J Rouse, Alan M Peaceman, Anthony Sciscione, Catherine Y Spong, Michael W Varner, Fergal D Malone, Jay D Iams, Brian M Mercer, John M Thorp, Yoram Sorokin, Marshall Carpenter, Julie Lo, Susan M Ramin, Margaret Harper
ABSTRACT

We sought to evaluate in women with twin gestation the relationship between 17-hydroxyprogesterone caproate (17-OHPC) concentration and gestational age at delivery and select biomarkers of potential pathways of drug action. Blood was obtained between 24-28 weeks (epoch 1) and 32-35 weeks (epoch 2) in 217 women with twin gestation receiving 17-OHPC or placebo. Gestational age at delivery and concentrations of 17-OHPC, 17-hydroxyprogesterone, progesterone, C-reactive protein (CRP), and corticotrophin-releasing hormone were assessed. Women with higher concentrations of 17-OHPC delivered at earlier gestational ages than women with lower concentrations (P < .001). Women receiving 17-OHPC demonstrated significantly higher (P = .005) concentrations of CRP in epoch 1 than women receiving placebo but CRP values were similar in epoch 2 in both groups. A highly significant (P < .0001) positive relationship was observed between 17-OHPC concentration and progesterone and 17-hydroxyprogesterone concentrations at both epochs. Corticotropin-releasing hormone concentrations did not differ by treatment group. 17-OHPC may adversely impact gestational age at delivery in women with twin gestation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
17α-Hydroxyprogesterone, ≥95%
Supelco
17α-Hydroxyprogesterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®